Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

MPN

Feature Video
Katie Kosko
The Food and Drug Administration has approved Nplate for pediatric patients 1 year of age and older with immune thrombocytopenia who have had an insufficient response to medications, such as corticosteroids,or surgery to remove the spleen. 
Brielle Benyon
More than 40 percent of patients with a myeloproliferative neoplasm reported that they were unsatisfied with their current pain management strategy.
Brielle Benyon
In the MEASURE trial, researchers examined the affect symptom burden associated with myeloproliferative neoplasms has on patients’ lives.
Brielle Benyon
For this episode of the CURE Talks Cancer podcast, we spoke with Scott Hamilton, an Olympic gold medalist, cancer survivor and founder of the Scott Hamilton CARES Foundation
Beth Fand Incollingo
At the MPN Heroes Event, Olympic skater Scott Hamilton discusses importance of advocacy and research.
Srdan Verstovsek, M.D., Ph.D.
While Jakafi has been providing promising outcomes so far, there are still some side effects that patients and providers should look out for.
Kristie L. Kahl
A Danish study demonstrated smokers were 2.5 times more likely to develop a myeloproliferative neoplasm compared with their non-smoking counterparts.
Katie Kosko
Two treatments that may help patients with a potentially deadly blood cancer live longer and prevent the incidence of thrombosis (blood clots) are being underused.
Jessica Skarzynski
After seeing encouraging phase 1 results, the phase 2 portion of a clinical trial currently evaluating the efficacy of the BET inhibitor CPI-0610 in patients with myelofibrosis has been enhanced and expanded.
Brielle Urciuoli
For many patients with polycythemia vera, hydroxyurea is a beneficial first-line treatment. But that’s not the case for everyone. One expert discusses which drugs should be used next.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other